
Galvanize Therapeutics, a healthcare company developing pulsed electric field (PEF) technology to treat cancer and chronic diseases, has raised $130 million in an oversubscribed Series D funding round.
The round was led by HealthQuest Capital, an investment firm focused on growing healthcare companies. Olympus Innovation Ventures and Braidwell LP also joined the round as new investors.
Several existing investors also participated in the funding. These include Sofinnova Partners, Norwest, Elevage Medical Technologies, Ally Bridge Group, Perceptive Advisors, Janus Henderson Investors, Longaeva Partners, Fidelity Management & Research Company and T. Rowe Price Associates.
“This financing marks an important inflection point for Galvanize,” said Doug Godshall, Chairman and Chief Executive Officer of Galvanize Therapeutics. “We’ve built a strong foundation with Aliya, demonstrating the potential of our PEF technology through growing physician adoption, commercial execution, and an expanding body of clinical evidence. This investment positions us to accelerate our growth and pursue our broader vision of expanding the impact of PEF across oncology and chronic disease. We’re grateful for the continued confidence of our investors as we enter this next phase of growth.”
“We have followed Galvanize’s progress closely over the years and are thrilled to back the company as it enters its next phase of growth,” said Garheng Kong, MD, PhD, Founder and Managing Partner of HealthQuest Capital. “Galvanize has built a differentiated PEF platform with the potential to meaningfully advance care in interventional oncology and pulmonology. We are excited to partner with the exceptional team as they expand the reach and impact of their innovative technology.”
Galvanize Therapeutics is developing pulsed electric field (PEF) technology to help treat cancer and chronic lung diseases. The technology uses electrical energy to target specific cells and support new treatment approaches.
Headquartered in Redwood City, California, the company is bringing its Aliya PEF platform to the US market. It is also working on new technologies and treatment applications for cancer and other chronic diseases.